Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 4/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 5/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26046982 | 0.94 | ACSS2 (0.56) | ACSS2GLAALOX15KMT2ADHODH | |
| SCHEMBL26046975 | 0.92 | ACSS2 (0.65) | ACSS2GLAALOX15RIPK1 | |
| SCHEMBL23832307 | 0.88 | ACSS2 (0.64) | ACSS2GLAALOX15KMT2APOLB | |
| SCHEMBL26047022 | 0.86 | ACSS2 (0.47) | ACSS2GLAALOX15 | |
| SCHEMBL30640950 | 0.82 | ACSS2 (0.65) | ACSS2GLAALOX15KMT2AMAPT | |
| SCHEMBL23843514 | 0.82 | ACSS2 (0.65) | ACSS2GLAALOX15KMT2AMAPT | |
| SCHEMBL26044506 | 0.80 | ACSS2 (0.80) | ACSS2GLAALOX15RIPK1SMN1; SMN2 | |
| SCHEMBL25434252 | 0.79 | ACSS2 (0.68) | ACSS2GLAALOX15KMT2ASMN1; SMN2 | |
| SCHEMBL23843491 | 0.78 | ACSS2 (0.79) | ACSS2GLAALOX15MAPT | |
| SCHEMBL30640961 | 0.78 | ACSS2 (0.79) | ACSS2GLAALOX15MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271956-A1 | AMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271956-A1 | AMIDE DERIVATIVES | BRCA1, HRAS, PCNA | ACSS2 201/4885GLA 1335/4885ALOX15 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.